

What is claimed is:

1. A pharmaceutical composition comprising (i) the AT 1-antagonist valsartan or a pharmaceutically acceptable salt thereof and (ii) a NEP inhibitor or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
2. The pharmaceutical composition of claim 1, wherein the NEP inhibitor is selected from the group consisting of SQ 28,603, N-[N-[1(S)-carboxyl-3-phenylpropyl]-S-phenylalanyl]-S-isoserine, N-[N-[(1S)-carboxy-2-phenylethyl]-S-phenylalanyl]-β-alanine, N-[2(S)-mercaptomethyl-3-(2-methylphenyl)-propionyl]methionine, (cis-4-[[[1-[2-carboxy-3-(2-methoxyethoxy)propyl]-cyclopentyl]carbonyl]amino]-cyclohexanecarboxylic acid), thiorphan, retro-thiorphan, phosphoramidon, SQ 29072, N-(3-carboxy-1-oxopropyl)-(4S)-p-phenylphenylmethyl)-4-amino-2R-methylbutanoic acid ethyl ester, (S)-cis-4-[1-[2-(5-indanyloxycarbonyl)-3-(2-methoxyethoxy)propyl]-1-cyclopentanecarboxamido]-1-cyclohexanecarboxylic acid, 3-(1-[6-endo-hydroxymethylbicyclo[2.2.1]heptane-2-exo-carbamoyl]cyclopentyl)-2-(2-methoxyethyl)propanoic acid, N-(1-(3-(N-t-butoxycarbonyl-(S)-prolylamino)-2(S)-t-butoxy-carbonylpropyl)cyclopentanecarbonyl)-O-benzyl-(S)-serine methyl ester, 4-[[2-(Mercaptomethyl)-1-oxo-3-phenylpropyl]amino]benzoic acid, 3-[1-(Cis-4-carboxycarbonyl-cis-3-butylcyclohexyl-r-1-carboamoyl)cyclopentyl]-2S-(2-methoxyethoxymethyl)propanoic acid, N-((2S)-2-(4-biphenylmethyl)-4-carboxy-5-phenoxyvaleryl)glycine, N-(1-(N-hydroxycarbamoylmethyl)-1-cyclopentanecarbonyl)-L-phenylalanine, (S)-(2-biphenyl-4-yl)-1-(1H-tetrazol-5-yl)ethylamino) methylphosphonic acid, (S)-5-(N-(2-(phosphonomethylamino)-3-(4-biphenyl)propionyl)-2-aminoethyl)tetrazole, β-Alanine, 3-[1,1'-biphenyl]-4-yl-N-[diphenoxypyrophosphinyl)methyl]-L-alanyl, N-(2-carboxy-4-thienyl)-3-mercaptop-2-benzylpropanamide, 2-(2-mercaptomethyl-3-phenylpropionamido)thiazol-4-ylcarboxylic acid, (L)-(1-((2,2-dimethyl-1,3-dioxolan-4-yl)-methoxy)carbonyl)-2-phenylethyl)-L-phenylalanyl)-β-alanine, N-[N-[(L)-[1-[(2,2-dimethyl-1,3-dioxolan-4-yl)-methoxy]carbonyl]-2-phenylethyl]-L-phenylalanyl]-R)-alanine, N-[N-[(L)-1-carboxy-2-phenylethyl]-L-phenylalanyl]-R)-alanine, N-[2-acetylthiomethyl-3-(2-methyl-phenyl)propionyl]-methionine ethyl ester, N-[2-mercaptomethyl-3-(2-methylphenyl)propioyl]-methionine, N-[2(S)-mercaptomethyl-3-(2-methylphenyl)propanoyl]-S-isoserine, N-(S)-[3-mercaptop-2-(2-methylphenyl)propionyl]-S-2-methoxy-(R)-alanine, N-[1-[[1(S)-benzyloxycarbonyl-3-phenylpropyl]amino]cyclopentylcarbonyl]-S-isoserine, N-[1-[[1(S)-carbonyl-3-

phenylpropylamino]-cyclopentylcarbonyl]-(S)-isoserine, 1,1'-[dithiobis-[2(S)-(2-methylbenzyl)-1-oxo-3,1-propanediyl]]-bis-(S)-isoserine, 1,1'-[dithiobis-[2(S)-(2-methylbenzyl)-1-oxo-3,1-propanediyl]]-bis-(S)-methionine, N-(3-phenyl-2-(mercaptomethyl)-propionyl)-(S)-4-(methylmercapto)methionine, N-[2-acetylthiomethyl-3-phenyl-propionyl]-3-aminobenzoic acid, N-[2-mercaptomethyl-3-phenyl-propionyl]-3-aminobenzoic acid, N-[1-(2-carboxy-4-phenylbutyl)-cyclopentanecarbonyl]-(S)-isoserine, N-[1-(acetylthiomethyl)cyclopentane-carbonyl]-(S)-methionine ethyl ester, 3(S)-[2-(acetylthiomethyl)-3-phenyl-propionyl]amino- $\epsilon$ -caprolactam and N-(2-acetylthiomethyl-3-(2-methylphenyl)propionyl)-methionine ethyl ester, or in each case, a pharmaceutically acceptable salt thereof.

3. The pharmaceutical composition of claim 2, wherein the NEP inhibitor is N-(3-carboxy-1-oxopropyl)-(4S)-p-phenylphenylmethyl)-4-amino-2R-methylbutanoic acid ethyl ester is a triethanolamine or tris(hydroxymethyl)aminomethane salt thereof or N-(3-carboxy-1-oxopropyl)-(4S)-p-phenylphenylmethyl)-4-amino-2R-methylbutanoic acid or a pharmaceutically acceptable salt thereof.
4. The pharmaceutical composition of claim 1 further comprising a diuretic.
5. A kit comprising in separate containers in a single package pharmaceutical compositions comprising in one container a pharmaceutical composition comprising a NEP inhibitor and in a second container a pharmaceutical composition comprising valsartan.
6. A method for the treatment or prevention of a condition or disease selected from the group consisting of hypertension, heart failure such as (acute and chronic) congestive heart failure, left ventricular dysfunction and hypertrophic cardiomyopathy, diabetic cardiac myopathy, supraventricular and ventricular arrhythmias, atrial fibrillation, atrial flutter, detrimental vascular remodeling, myocardial infarction and its sequelae, atherosclerosis, angina (whether unstable or stable), renal insufficiency (diabetic and non-diabetic), heart failure, angina pectoris, diabetes, secondary aldosteronism, primary and secondary pulmonary hypertension, renal failure conditions, such as diabetic nephropathy, glomerulonephritis, scleroderma, glomerular sclerosis, proteinuria of primary renal disease, and also renal vascular hypertension, diabetic retinopathy, the management of other vascular disorders, such as migraine, peripheral vascular disease, Raynaud's disease, luminal hyperplasia, cognitive dysfunction (such as Alzheimer's), glaucoma and stroke,

comprising administering a therapeutically effective amount of combination of (i) the AT 1-antagonists valsartan or a pharmaceutically acceptable salt thereof and (ii) a NEP inhibitor or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier to a mammal in need of such treatment.

7. A method as claimed in claim 6, wherein the NEP inhibitor is selected from the group consisting of SQ 28,603, N-[N-{1(S)-carboxyl-3-phenylpropyl}-(S)-phenylalanyl]-(S)-isoserine, N-[N-[((1S)-carboxy-2-phenyl)ethyl]-(S)-phenylalanyl]-β-alanine, N-[2(S)-mercaptomethyl-3-(2-methylphenyl)-propionyl]methionine, (cis-4-[[[1-[2-carboxy-3-(2-methoxyethoxy)propyl]-cyclopentyl]carbonyl]amino]-cyclohexanecarboxylic acid), thiorphane, retro-thiorphane, phosphoramidon, SQ 29072, N-(3-carboxy-1-oxopropyl)-(4S)-p-phenylphenylmethyl)-4-amino-2R-methylbutanoic acid ethyl ester, (S)-cis-4-[1-[2-(5-indanyloxycarbonyl)-3-(2-methoxyethoxy)propyl]-1-cyclopentanecarboxamido]-1-cyclohexanecarboxylic acid, 3-(1-[6-endo-hydroxymethylbicyclo[2.2.1]heptane-2-exo-carbamoyl]cyclopentyl)-2-(2-methoxyethyl)propanoic acid, N-(1-(3-(N-t-butoxycarbonyl-(S)-proylamino)-2(S)-t-butoxy-carbonylpropyl)cyclopentanecarbonyl)-O-benzyl-(S)-serine methyl ester, 4-[[2-(Mercaptomethyl)-1-oxo-3-phenylpropyl]amino]benzoic acid, 3-[1-(Cis-4-carboxycarbonyl-cis-3-butylcyclohexyl-r-1-carboamoyl)cyclopentyl]-2S-(2-methoxyethoxymethyl)propanoic acid, N-((2S)-2-(4-biphenylmethyl)-4-carboxy-5-phenoxyvaleryl)glycine, N-(1-(N-hydroxycarbamoylmethyl)-1-cyclopentanecarbonyl)-L-phenylalanine, (S)-(2-biphenyl-4-yl)-1-(1H-tetrazol-5-yl)ethylamino) methylphosphonic acid, (S)-5-(N-(2-(phosphonomethylamino)-3-(4-biphenyl)propionyl)-2-aminoethyl)tetrazole, β-Alanine, 3-[1,1'-biphenyl]-4-yl-N-[diphenoxypyrophosphinyl)methyl]-L-alanyl, N-(2-carboxy-4-thienyl)-3-mercaptop-2-benzylpropanamide, 2-(2-mercaptomethyl-3-phenylpropionamido)thiazol-4-ylcarboxylic acid, (L)-(1-((2,2-dimethyl-1,3-dioxolan-4-yl)-methoxy)carbonyl)-2-phenylethyl)-L-phenylalanyl]-β-alanine, N-[N-[(L)-1-[(2,2-dimethyl-1,3-dioxolan-4-yl)-methoxy]carbonyl]-2-phenylethyl]-L-phenylalanyl]- (R)-alanine, N-[N-[(L)-1-carboxy-2-phenylethyl]-L-phenylalanyl]- (R)-alanine, N-[2-acetylthiomethyl-3-(2-methyl-phenyl)propionyl]-methionine ethyl ester, N-[2-mercaptomethyl-3-(2-methylphenyl)propioyl]-methionine, N-[2(S)-mercaptomethyl-3-(2-methylphenyl)propanoyl]-(S)-isoserine, N-(S)-[3-mercato-2-(2-methylphenyl)propionyl]-(S)-2-methoxy-(R)-alanine, N-[1-[(1(S)-benzyloxycarbonyl)-3-phenylpropyl]amino]cyclopentylcarbonyl]-(S)-isoserine, N-[1-[(1(S)-carbonyl-3-phenylpropyl)amino]-cyclopentylcarbonyl]-(S)-isoserine, 1,1'-[dithiobis-[2(S)-(2-methylbenzyl)-

1-oxo-3,1-propanediyl]]-bis-(S)-isoserine, 1,1'-[dithiobis-[2(S)-(2-methylbenzyl)-1-oxo-3,1-propanediyl]]-bis-(S)-methionine, N-(3-phenyl-2-(mercaptomethyl)-propionyl)-(S)-4-(methylmercapto)methionine, N-[2-acetylthiomethyl-3-phenyl-propionyl]-3-aminobenzoic acid, N-[2-mercaptomethyl-3-phenyl-propionyl]-3-aminobenzoic acid, N-[1-(2-carboxy-4-phenylbutyl)-cyclopentanecarbonyl]- (S)-isoserine, N-[1-(acetylthiomethyl)cyclopentane-carbonyl]- (S)-methionine ethyl ester, 3(S)-[2-(acetylthiomethyl)-3-phenyl-propionyl]amino- $\epsilon$ -caprolactam and N-(2-acetylthiomethyl-3-(2-methylphenyl)propionyl)-methionine ethyl ester, and in each case, a pharmaceutically acceptable salt thereof.

8. The method of claim 6, wherein the NEP inhibitor is N-(3-carboxy-1-oxopropyl)-(4S)-p-phenylphenylmethyl)-4-amino-2R-methylbutanoic acid ethyl ester is a triethanolamine or tris(hydroxymethyl)aminomethane salt thereof or N-(3-carboxy-1-oxopropyl)-(4S)-p-phenylphenylmethyl)-4-amino-2R-methylbutanoic acid or a pharmaceutically acceptable salt thereof.

9. A triethanolamine salt of N-(3-carboxy-1-oxopropyl)-(4S)-p-phenylphenylmethyl)-4-amino-2R-methylbutanoic acid ethyl ester

10. A tris(hydroxymethyl)aminomethane salt of N-(3-carboxy-1-oxopropyl)-(4S)-p-phenylphenylmethyl)-4-amino-2R-methylbutanoic acid ethyl ester.


11. A pharmaceutical composition comprising the salt of claim 9.

12. A pharmaceutical composition comprising the salt of claim 10.

13. A pharmaceutical composition substantially as herein described and exemplified.

14. A method for the treatment or prevention of a condition or disease selected from the group consisting of hypertension, substantially as herein described and exemplified.

Dated this 9 day of July 2004



(R R NAIR)  
Of DePENNING & DePENNING  
AGENT FOR THE APPLICANTS